Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 210

Results For "NSE"

2557 News Found

Innovent Biologics and AnHeart Therapeutics receive NMPA breakthrough designation for taletrectinib
Biotech | March 01, 2022

Innovent Biologics and AnHeart Therapeutics receive NMPA breakthrough designation for taletrectinib

The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors


Thermo Fisher Scientific extends partnership with Symphogen to support biopharma
Medical Device | March 01, 2022

Thermo Fisher Scientific extends partnership with Symphogen to support biopharma

Thermo Fisher and Symphogen extend their collaboration using innovative and efficient workflows to improve data confidence, aiding the creation of new cancer treatments


Biocon Biologics acquires Viatris’ biosimilar assets for up to US $ 3.3 billion
News | February 28, 2022

Biocon Biologics acquires Viatris’ biosimilar assets for up to US $ 3.3 billion

BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets


Researchers develop a fast, efficient tech to remove pollutants from water
Sustainability | February 28, 2022

Researchers develop a fast, efficient tech to remove pollutants from water

The method shows the removal of seven types of PFAS – even when all of them are found in the same unit of fluid – at a level of efficiency that approaches 90%, and it does so within a few minutes


Cabinet approves Ayushman Bharat Digital Mission at an outlay of Rs 1,600 cr.
Policy | February 27, 2022

Cabinet approves Ayushman Bharat Digital Mission at an outlay of Rs 1,600 cr.

Citizens will be able to create their ABHA (Ayushman Bharat Health Account) numbers, to which their digital health records can be linked


DiscGenics presents positive Phase1/2 study of Cell therapy for degenerative disc disease
Biotech | February 27, 2022

DiscGenics presents positive Phase1/2 study of Cell therapy for degenerative disc disease

Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection


LivaNova announces first patient implanted in OSPREY clinical study
Medical Device | February 27, 2022

LivaNova announces first patient implanted in OSPREY clinical study

Study to evaluate effectiveness of hypoglossal nerve stimulation


Cantex and Harvard's Wyss Institute to expand development of Azeliragon
News | February 27, 2022

Cantex and Harvard's Wyss Institute to expand development of Azeliragon

Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.


Mandaviya launches ICMR/ DHR policy on biomedical innovation & entrepreneurship
Policy | February 25, 2022

Mandaviya launches ICMR/ DHR policy on biomedical innovation & entrepreneurship

This policy will ensure multi-disciplinary collaboration, promote start-up culture and develop an innovation-led ecosystem at medical institutes across the country


Canada approves plant-based Covid-19 vaccine
News | February 25, 2022

Canada approves plant-based Covid-19 vaccine

Medicago and GSK collaborated on Covifenz, an adjuvanted plant-based vaccine